|
|
NEWS
RECALLS
COMPLAINT FORM
SCAM ALERTS
RESOURCES
Small Claims Guide Class Actions Lemon Laws FAQ Newsletters |
Share |
| Automotive Education Employment Electronics Family Finance Health Homeowners Insurance Pets Shopping Travel |
|
|
|
![]() |
Medical Journal Warns Obesity Guidelines May Endanger Children |
|||||||||||||
|
June 16, 2006
Two articles in the British Medical Journal suggest it is, and question the financial links between the organization promoting new obesity guidelines and the pharmaceutical industry. The articles claim an influential expert committee of the American Medical Association has "tentatively decided" to reclassify obesity definitions. This, the author contends, will result in healthy children being categorized as medically overweight or obese, meaning that approximately a quarter of toddlers and two fifths of children aged 6-11 in America will be classed as having the disease. Author Ray Moynihan, who has previously written about drug companies promoting an increasing reliance on medications to the public, says the U.S. proposals have been greeted with alarm by some senior public health academics who have written to the committee. Dr. Jenny O'Dea from the University of Sydney, for instance, warned that labeling children as overweight or obese can lead to stigmatization, eating problems, and avoidance of exercise. Moynihan maintains that one of the prime movers behind the proposed changes being considered by the expert committee is Dr. William Dietz, a senior member of the International Obesity Task Force. In a second article Moynihan claims the high profile and highly influential Task Force, which has close ties to the World Health Organization, was set up in the mid-1990s with the help of grants from three drug companies and continues to benefit from drug company sponsorship. Now merged with another international obesity forum, the Task Force reportedly gets two thirds of its funding from pharmaceutical giants Roche and Abbott. Roche makes the anti-obesity drug Xenical (orlistat), and Abbott makes the appetite suppressant Reductil (sibutramine hydrochloride). Over recent years, the article states, drug company sponsorship is likely to have amounted to "millions". The Task Force has responded to Moynihan's questions about its funding, saying that it has made no secret of the grants it has received from drug companies and emphasizing that an internal ethical scrutiny system ensures independence from sponsors. Report Your Experience
|
|||||||||||||
Advertisement
|
|
Custom Search
|
||||
|
AUTOMOTIVE Dealers Manufacturers Service Extended Warranties Lemon Laws Recalls Tires Transporters FAMILY Aging Children, Parenting Recalls Dating Education Entertainment Pets Weddings |
FINANCE Annuities Banks Credit Cards Debt Collection Debt Counseling Insurance Investing Loans Mortgages Payday Loans Student Loans Tax Prep HEALTH Doctors Drugs, Pharmacies Health Clubs Hearing Care Hospitals Nursing Homes Nutrition, Diets Vision Care Weight Loss |
HOUSE & HOME Appliances Cookware Furniture Home Improvements Lawn & Garden Movers Pools & Spas Realtors, Rental Agents Recalls Utilities ELECTRONICS Cable TV/DBS Cameras Cell Phones Computers Home Electronics Internet Access Local Phone Service Long Distance VoIP |
SHOPPING In-Home Online Retail Stores Sporting Goods Supermarkets Telemarketers TRAVEL Airlines Bus Lines Car Rental Cruises Hotels Travel Agents Trains RESOURCES Class Actions Complaint Form Small Claims Guide Lemon Laws |
CONSUMER NEWS Latest News Automotive Telecom Financial Health Homeowners Scams Seniors Travel More ... RECALLS Automotive Children's Products Drugs Food Household Products Sporting Goods ABOUT US FAQ Privacy Policy Advertise With Us Newsroom Syndication Terms of Use |
Terms of Use Your use of this site constitutes acceptance of the Terms of Use
Copyright © 2003-2009 ConsumerAffairs.com Inc. All Rights Reserved. The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission. |
|